Results for tag: "Lung Cancer Liquid Biopsy"

'''Lung Cancer Liquid Biopsy''' is a segment within the pharmaceutical market focused on the minimally invasive detection and monitoring of lung cancer through the analysis of biomarkers present in a patient's blood or other bodily fluids. Liquid biopsies offer a valuable alternative to traditional tissue biopsies, which can be invasive, painful, and sometimes not feasible due to the tumor's location or a patient's health status. The technology primarily aims to identify and quantify circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other cancer-related molecules, which can help in early detection, treatment planning, and monitoring of response to therapies. This emerging technology is particularly important for the management of lung cancer, where early diagnosis can significantly improve treatment outcomes. Liquid biopsies have the potential to provide insights into tumor genetics, mutation profiles, and even the presence of potential resistance to certain treatments without the need for more invasive procedures. The market for lung cancer liquid biopsies is characterized by active research and development, with numerous clinical trials evaluating the efficacy and precision of these tests. In the lung cancer liquid biopsy space, there are several key players, including Guardant Health, Foundation Medicine, Illumina, and Roche's subsidiary Genentech, which are at the forefront of this technology. Other notable companies include Biocept, Thermo Fisher Scientific, and Personal Genome Diagnostics, all contributing to the advancement and availability of liquid biopsy options for lung cancer patients. Show Less Read more